심혈관 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2025-2033년)

Cardiovascular Devices Market Summary

The global cardiovascular devices market size was estimated at USD 53.7 billion in 2024 and is projected to reach USD 106.7 billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033. Cardiovascular disease is one of the most prevalent medical conditions worldwide.

In January 2024, the American Heart Association (AHA) reported that cardiovascular disease (CVD) was the leading cause of death in the U.S., claiming 931,578 lives, surpassing deaths from all cancers and chronic respiratory diseases combined. Therefore, cardiovascular devices are crucial in accurately detecting and mitigating heart disorders, fueling market expansion. The main drivers of this market include rapid technical development, an increase in affordable and effective devices, and rising demand for minimally invasive procedures.

The surge in the number of cases of chronic cardiovascular disorders contributes to the market growth. Increasing cardiovascular disorders have led to an increased demand for cardiovascular devices. Heart or coronary artery stents are among the most essential cardiovascular devices. They facilitate the treatment of cardiac illnesses considered a serious risk to life, namely heart attacks, coronary disease, atrial fibrillation, and the expansion of clogged arteries. In May 2024, the WHO reported that cardiovascular diseases (CVDs) are the top cause of disability and premature death in Europe, accounting for over 42.5% of annual deaths, around 10,000 daily. Men are nearly 2.5 times more likely to die from CVDs than women, with young people (ages 30-69) in Eastern Europe and Central Asia facing a nearly fivefold higher risk compared to their Western European counterparts.

Global Cardiovascular Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiovascular devices market report based on product and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic & Monitoring Devices
• ECG
• Implantable Cardiac Monitors
• Holter Monitors
• Mobile Cardiac Telemetry
• MRI
• Cardiovascular Ultrasound
  • 2D
  • 3D/4D
  • Doppler
• Cardiac Diagnostic Catheters
• PET Scanner
• Surgical Devices
• Cardiac Resynchronization Therapy (CRT)
  • CRT-Defibrillator
  • CRT-Pacemaker
• Implantable Cardioverter Defibrillators (ICDs)
  • Single Chamber ICDs
  • Dual Chamber ICDs
• Pacemakers
  • Conventional Pacemakers
  • Leadless Pacemakers
• Coronary Stents
• Catheters
• Guidewires
• Cannula
• Valves
• Occlusion Devices
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Norway
• Denmark
• Asia Pacific
• Japan
• China
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Mexico
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cardiovascular Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Increasing prevalence of cardiovascular diseases
    • 3.3.1.2. Technological advancements
    • 3.3.1.3. Aging population
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. Regulatory challenges
    • 3.3.2.2. High cost of development
• 3.4. Cardiovascular Devices Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape
  • 3.4.3. Pipeline Analysis

Chapter 4. Cardiovascular Devices: Product Estimates & Trend Analysis

• 4.1. Cardiovascular Devices Market: Product Key Takeaways
• 4.2. Cardiovascular Devices Market: Product Movement & Market Share Analysis, 2024 & 2033
• 4.3. Diagnostic and Monitoring Devices
  • 4.3.1. Diagnostic and monitoring devices estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.1. ECG
      • 4.3.1.1.1. ECG market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.2. Implantable Cardiac Monitors
      • 4.3.1.2.1. Implantable cardiac monitors market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.3. Holter Monitors
      • 4.3.1.3.1. Holter monitors market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.4. Mobile Cardiac Telemetry
      • 4.3.1.4.1. Mobile cardiac telemetry market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.5. MRI
      • 4.3.1.5.1. MRI estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.6. Cardiovascular Ultrasound
      • 4.3.1.6.1. Cardiovascular ultrasound market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.3.1.6.2. 2D
        • 4.3.1.6.2.1. 2D market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.3.1.6.3. 3D/4D
        • 4.3.1.6.3.1. 3D/4D market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.3.1.6.4. Doppler
        • 4.3.1.6.4.1. Doppler market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.7. Cardiac Diagnostic Catheters
      • 4.3.1.7.1. Cardiac diagnostic catheters market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.3.1.8. PET Scanner
      • 4.3.1.8.1. PET scanner market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.4. Surgical Devices
  • 4.4.1. Surgical devices market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.1. Cardiac Resynchronization Therapy (CRT)
      • 4.4.1.1.1. Cardiac resynchronization therapy (CRT) market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.1.2. CRT-Defibrillator
        • 4.4.1.1.2.1. CRT-defibrillator market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.1.3. CRT-Pacemaker
        • 4.4.1.1.3.1. CRT-pacemaker market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.2. Implantable Cardioverter Defibrillators (ICDs)
      • 4.4.1.2.1. Implantable cardioverter defibrillators (ICDs) market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.2.2. Single Chamber ICDs
        • 4.4.1.2.2.1. Single chamber ICDs market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.2.3. Dual Chamber ICDs
        • 4.4.1.2.3.1. Dual chamber ICDs market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.3. Pacemakers
      • 4.4.1.3.1. Pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.3.2. Conventional Pacemakers
        • 4.4.1.3.2.1. Conventional pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.4.1.3.3. Leadless Pacemakers
        • 4.4.1.3.3.1. Leadless pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.4. Coronary Stents
      • 4.4.1.4.1. Coronary stents market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.5. Catheters
      • 4.4.1.5.1. Catheters market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.6. Guidewires
      • 4.4.1.6.1. Guidewires market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.7. Cannula
      • 4.4.1.7.1. Cannula market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.8. Valves
      • 4.4.1.8.1. Valves market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.1.9. Occlusion devices
      • 4.4.1.9.1. Occlusion devices market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Cardiovascular Devices Market: Regional Estimates & Trend Analysis by Country and Product

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.6. Norway
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.8. Denmark
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.5. South Korea
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.3. Mexico
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Vendor Landscape
  • 6.2.1. List of key distributors and channel partners
  • 6.2.2. Key customers
  • 6.2.3. Key company market share analysis, 2024
• 6.3. Market Participant Categorization
  • 6.3.1. Abbott
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Product benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. GE HealthCare
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Product benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Edwards Lifesciences Corporation
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Product benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. W. L. Gore & Associates, Inc.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Siemens Healthcare GmbH
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. BIOTRONIK SE & Co. KG
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Canon Medical Systems Asia Pte. Ltd.
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. B. Braun SE
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. LivaNova PLC
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Cardinal Health
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Medtronic
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Boston Scientific Corporation
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives